Search Result

Results for "

SAH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Carbonic Anhydrase (1) Caspase (1) Cathepsin (2) DNA Methyltransferase (2) Endogenous Metabolite (7) ERK (1) HBV (1) Histone Methyltransferase (1) HSV (1) Lipoxygenase (1) Melanocortin Receptor (2) Methionine Adenosyltransferase (MAT) (1) MMP (2) Nucleoside Antimetabolite/Analog (1) Parasite (1) Ras (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SARS-CoV (3) Small Interfering RNA (siRNA) (1) SOS1 (2) TGF-beta/Smad (2) TGF-β Receptor (2) Trk Receptor (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (4) Infection (5) Inflammation/Immunology (5) Metabolic Disease (9) Neurological Disease (8)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19528

*SAH* Maximum Cited Publications 16 Publications Verification SAH (S-Adenosylhomocysteine)	Endogenous Metabolite	Metabolic Disease
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-19528S

SAH-d4 SAH (S-Adenosylhomocysteine)-d₄	Endogenous Metabolite	Metabolic Disease
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-19528S2

SAH-13C10	Endogenous Metabolite	Metabolic Disease
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-P2265A

SAH-SOS1A TFA	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-149048

Adenosylhomocysteinase SAHH; AHCY	Endogenous Metabolite HBV	Infection Metabolic Disease
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients .

HY-P10359A

TAT-QFNP12 acetate	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 acetate is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-P2265

SAH-SOS1A	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10359

TAT-QFNP12	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-18684

SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine	Nucleoside Antimetabolite/Analog HSV Parasite	Infection Metabolic Disease Cancer
SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies .

HY-122816

HLY78 10+ Cited Publications	Wnt β-catenin Apoptosis	Cardiovascular Disease Neurological Disease Cancer
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .

HY-RS00207

ACSM3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ACSM3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSM3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ACSM3 Human Pre-designed siRNA Set A ACSM3 Human Pre-designed siRNA Set A

HY-W010347

L-Homocysteine 5+ Cited Publications	Endogenous Metabolite Cathepsin	Cardiovascular Disease Inflammation/Immunology
L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia .

HY-W010347R

L-Homocysteine (Standard)	Reference Standards Endogenous Metabolite Cathepsin	Cardiovascular Disease Inflammation/Immunology
L-Homocysteine (Standard) is the analytical standard of L-Homocysteine. This product is intended for research and analytical applications. L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

HY-B0553

Methazolamide 4 Publications Verification L584601	Carbonic Anhydrase Apoptosis Reactive Oxygen Species (ROS) Caspase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a K_i of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage .

HY-170523

RU-0415529	SARS-CoV DNA Methyltransferase	Infection
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .

HY-162177

SARS-CoV-2-IN-78	SARS-CoV	Infection
SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .

HY-101446

HIOC	Trk Receptor ERK Apoptosis	Neurological Disease
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .

HY-136145

FIDAS-3	Wnt	Cancer
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC₅₀ of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities .

HY-111310

ML351 1 Publications Verification	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-136144

FIDAS-5 4 Publications Verification	Methionine Adenosyltransferase (MAT)	Cancer
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-170524

TDI-015051	SARS-CoV DNA Methyltransferase	Infection
TDI-015051 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ ≤0.15 nM. TDI-015051 inhibits SARS-CoV-2 NSP14 in Huh-7.5 cell (EC₅₀=11.4 nM) and in ACE2-TMPRSS2 expressing A549 cell (EC₅₀=64.7 nM). TDI-015051 also inhibits other coronaviruses like α-hCoV-NL63, α-hCoV-229E and β-hCoV-MERS with IC₅₀s of 1.7, 2.6 and 3.6 nM, respectively. TDI-015051 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and viral replication, and exhibits anti-infectious activity in mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-P2265A

SAH-SOS1A TFA	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10359A

TAT-QFNP12 acetate	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 acetate is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P2265

SAH-SOS1A	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10359

TAT-QFNP12	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-19528

*SAH* 15+ Cited Publications SAH (S-Adenosylhomocysteine)	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Disease markers Metabolic Disease Amino acids Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Disease markers Amino acids Nervous System Disorder Endogenous metabolite	Reference Standards Endogenous Metabolite
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-149048

Adenosylhomocysteinase SAHH; AHCY	Infection Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite HBV
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients .

HY-W010347

L-Homocysteine 5+ Cited Publications	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Cathepsin
L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia .

HY-W010347R

L-Homocysteine (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Cathepsin
L-Homocysteine (Standard) is the analytical standard of L-Homocysteine. This product is intended for research and analytical applications. L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

Cat. No.	Product Name	Chemical Structure

HY-19528S

SAH-d4
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-19528S2

SAH-13C10
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P85414

	ACSM3 Antibody (YA5106) ACSM3; SAH; Acyl-coenzyme A synthetase ACSM3; mitochondrial; Acyl-CoA synthetase medium-chain family member 3; Butyrate--CoA ligase 3; Butyryl-coenzyme A synthetase 3; Middle-chain acyl-CoA synthetase 3; Protein SA homolog	WB	Human, Mouse, Rat, Bovine, Pig
	ACSM3 Antibody (YA5106) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ACSM3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-19528

*SAH* 15+ Cited Publications SAH (S-Adenosylhomocysteine)		Nucleoside Analogs Adenosine
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-RS00207

ACSM3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ACSM3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSM3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SAH

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products